CombiMatrix Corporation (CBMX)
CBMX reported that it has been selected by ProPath(R) to provide its chromosomal microarray analysis (CMA) testing for miscarriage analysis for ProPath patients.
ProPath is a provider of pathology services to clinicians, hospitals, reference laboratories and medical facilities nationwide, committed to providing comprehensive, high quality diagnostics services and CMA testing for miscarriage analysis. Also called Products of Conception testing, this will be an important new addition to ProPath's suite of women's health diagnostics.
According to CBMX , CMA testing for genetic abnormalities is quickly becoming the standard of care at leading diagnostic labs throughout the country, especially important in the case of stillbirths or miscarriages because it can provide parents valuable information about future pregnancies.
CBMX provides valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care -- specializing in miscarriage analysis, prenatal and pediatric healthcare.
More about CombiMatrix Corporation (CBMX) at www.combimatrix.com
**
Crown Equity Holdings Inc. (CRWE)
"Social networking" has been around forever. It's the simple act of expanding the number of people you know by meeting your friends' friends, their friends' friends and so on. A social networking service is a platform to build social networks or social relations among people who, for example, share interests, activities, backgrounds, or real-life connections.
CRWE is looking to deliver value for its stockholders in both the near and long term, targeting the multi-billion dollar social networking service market.
CRWE is currently developing a social networking service and phone app, CRWE Network ( CRWE-PR.com ), that is designed to target all the communities in every state of the United States, with its geographic focus starting in Southern California and Las Vegas Nevada.
CRWE Network Travel Search is an information source for travelers searching for hotels, airline tickets, car rentals, cruise deals, Las Vegas events tickets, to find the cheapest vacations online
CRWE ‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .
**
Nautilus, Inc. (NLS)
Keep a close eye on NLS . The company reported sales growth in all segments of its business on its preliminary, unaudited results.
For the fourth quarter of 2013, NLS expects to report net sales of approximately $77.1 million, an 18.5% increase year over year, and non-GAAP fully diluted earnings per share from continuing operations are estimated to be in the range of $0.29 - $0.31 (excluding income tax expense of $0.04 per share), compared to $0.23 per share in the same period the prior year.
For the full year 2013, NLS expects net sales of approximate $218.8 million, a 12.8% increase year over year, and non-GAAP fully diluted earnings per share from continuing operations are expected to be in the range of $0.46 - $0.48 (excluding income tax benefit of $1.05 per share) versus $0.34 per share in 2012.
NLS is a global fitness products company providing innovative, quality solutions to help people achieve a healthy lifestyle.
More about Nautilus, Inc. (NLS) at www.nautilusinc.com
**
GW Pharmaceuticals plc (GWPH)
Spasticity is a symptom defined as loss of mobility, painful spasms, stiffness and / or weakness of muscles, occurring in over 80% of multiple sclerosis (MS) sufferers in the course of the disease. Spasticity can affect many aspects of the daily lives of patients with MS and is one of the main factors contributing to their distress and disability.
Ipsen and GWPH reported that they have entered into an exclusive agreement for Ipsen to promote and distribute Sativex(R), a sublingual cannabis extract spray intended for the treatment of spasticity due to multiple sclerosis (MS) in Latin America (excluding Mexico and the Islands of the Caribbean). GWPH will be responsible for commercial product supply to Ipsen.
Financial terms include an upfront payment to GWPH, regulatory and commercial milestone payments, and a long term supply price.
Sativex, developed and manufactured by GWPH , is already approved in 24 countries (principally in Europe) as a treatment of spasticity due to multiple sclerosis.
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
More about GW Pharmaceuticals plc (GWPH) at www.gwpharm.com .
**
Read Full Disclaimer at www.pennyomega.com/disclaimer
